These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29346605)

  • 41. Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
    Kim C; Prasad V
    JAMA Intern Med; 2015 Dec; 175(12):1992-4. PubMed ID: 26502403
    [No Abstract]   [Full Text] [Related]  

  • 42. Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
    Vokinger KN; Kesselheim AS
    Health Policy; 2019 Aug; 123(8):721-727. PubMed ID: 31229275
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relocating abroad. FDA sends staff overseas to help monitor imports.
    Lee J
    Mod Healthc; 2011 Oct; 41(43):32. PubMed ID: 22111150
    [No Abstract]   [Full Text] [Related]  

  • 44. Two-stage drug approval would reduce the risks.
    Frantz JA
    Nature; 2005 May; 435(7039):143. PubMed ID: 15889063
    [No Abstract]   [Full Text] [Related]  

  • 45. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 46. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
    Wallach JD; Ross JS; Naci H
    Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multisite clinical trials in strict accordance with GMP standards?
    Poe TA
    Drug Discov Today; 2003 Jul; 8(13):570-3. PubMed ID: 12850329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 50. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients?
    Schilsky RL
    J Clin Oncol; 2003 Oct; 21(20):3718-20. PubMed ID: 12963701
    [No Abstract]   [Full Text] [Related]  

  • 51. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 52. Generic drug approval: a US perspective.
    Nagori BP; Mathur V; Garg S
    Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The US Food and Drug Administration's Authorization of the First Cannabis-Derived Pharmaceutical: Are We Out of the Haze?
    Yang YT; Szaflarski JP
    JAMA Neurol; 2019 Feb; 76(2):135-136. PubMed ID: 30452525
    [No Abstract]   [Full Text] [Related]  

  • 55. The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?
    Gyawali B; Goldstein DA
    JAMA Oncol; 2018 May; 4(5):623-624. PubMed ID: 29522146
    [No Abstract]   [Full Text] [Related]  

  • 56. Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.
    Knopf K; Baum M; Shimp WS; Bennett CL; Faith D; Fishman ML; Hrushesky WJ
    BMJ; 2016 Dec; 355():i6286. PubMed ID: 28039123
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
    Browne TR
    Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
    [No Abstract]   [Full Text] [Related]  

  • 58. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 59. 2015 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2016 Feb; 15(2):73-6. PubMed ID: 26837582
    [No Abstract]   [Full Text] [Related]  

  • 60. Production of high-quality marketing applications: strategies for biotechnology companies working with contract research organizations.
    Hecker SJ; Preston C; Foote M
    Biotechnol Annu Rev; 2003; 9():269-77. PubMed ID: 14650931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.